Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sharon Cohen, MD, FRCPC. [LISTEN TIME: 14 minutes]
The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.
This episode, "Lecanemab Approved for Alzheimer Disease," features an exclusive interview with Sharon Cohen, MD, FRCPC, a behavioral neurologist and medical director of the Toronto Memory Program at the University of Toronto, and a trial investigator for Clarity AD, the phase 3 trial of lecanemab. Similar to its predecessor, lecanemab was approved via the accelerated approval pathway, with the application supported by data from the phase 2b proof-of-concept clinical trial, known as Study 201 (NCT01767311). The pivotal phase 3 Clarity AD trial (NCT03887455), which is anticipated to serve as supplementary data and is pending review by the FDA.1
Click here to subscribe to the Mind Moments® podcast. Be sure to leave a rating and review for the show. Thanks for listening!